GSK Gets UK Approval for Blenrep Combinations in Multiple Myeloma

MT Newswires Live04-18

GSK (GSK) said Thursday the UK's Medicines and Healthcare products Regulatory Agency has authorized the use of Blenrep combinations to treat relapsed or refractory multiple myeloma.

Blenrep is now approved for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, GSK said.

The regulator also approved the drug in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy, including lenalidomide, it added.

This authorization marks the first in the world for Blenrep in this treatment setting, the company said.

Price: 35.76, Change: +0.39, Percent Change: +1.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2528761728?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-18 00:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528761728","market":"sg","top_or_hot":-1,"title":"GSK Gets UK Approval for Blenrep Combinations in Multiple Myeloma","media":"MT Newswires Live","content":"<html><body><p> GSK (GSK) said Thursday the UK's Medicines and Healthcare products Regulatory Agency has authorized the use of Blenrep combinations to treat relapsed or refractory multiple myeloma.</p><p>Blenrep is now approved for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, GSK said.</p><p>The regulator also approved the drug in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy, including lenalidomide, it added.</p><p>This authorization marks the first in the world for Blenrep in this treatment setting, the company said.</p><p>Price: 35.76, Change: +0.39, Percent Change: +1.09</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Gets UK Approval for Blenrep Combinations in Multiple Myeloma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Gets UK Approval for Blenrep Combinations in Multiple Myeloma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-18 00:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> GSK (GSK) said Thursday the UK's Medicines and Healthcare products Regulatory Agency has authorized the use of Blenrep combinations to treat relapsed or refractory multiple myeloma.</p><p>Blenrep is now approved for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, GSK said.</p><p>The regulator also approved the drug in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy, including lenalidomide, it added.</p><p>This authorization marks the first in the world for Blenrep in this treatment setting, the company said.</p><p>Price: 35.76, Change: +0.39, Percent Change: +1.09</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2528761728","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528761728","pubTimestamp":1744905889,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GSK  said Thursday the UK's Medicines and Healthcare products Regulatory Agency has authorized the use of Blenrep combinations to treat relapsed or refractory multiple myeloma.Blenrep is now approved for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, GSK said.The regulator also approved the drug in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy, including lenalidomide, it added.This authorization marks the first in the world for Blenrep in this treatment setting, the company said.Price: 35.76, Change: +0.39, Percent Change: +1.09","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","GSK.UK":"葛兰素史克","GSK":"葛兰素史克","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"葛兰素史克(GSK)Blenrep组合治疗多发性骨髓瘤获得英国批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.6,"GSK":1},"content_text":"GSK (GSK) said Thursday the UK's Medicines and Healthcare products Regulatory Agency has authorized the use of Blenrep combinations to treat relapsed or refractory multiple myeloma.Blenrep is now approved for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, GSK said.The regulator also approved the drug in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy, including lenalidomide, it added.This authorization marks the first in the world for Blenrep in this treatment setting, the company said.Price: 35.76, Change: +0.39, Percent Change: +1.09","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2528761728","isCrawlerRequest":true}